R&D
RESEARCH & DEVELOPMENT
Hoba Therapeutics focus on development of two related neurotrophic growth factors, HB-086 and HB-097. The molecules constitute a unique family significantly differentiated from currently know neuronal growth factors.
HB-086 and HB-097 are expressed broadly in neonatal animals and to a more limited extent in discrete cell population in adult animals.
Published reports provide support for potential neuroprotective and neuroregenerative functions of the protein family
Through development of HB-086 and HB-097, Hoba Therapeutics goal is to improve quality of life for patients suffering from neuropathic pain and CNS disorders
HB-086 and HB-097
HB-086 is a 31 kDa secreted monomeric protein which promotes neurite outgrowth from dorsal root ganglion cultures. In the central nervous system, HB-086 promotes glial differentiation.
The receptor and exact mechanism of action is unknown, but lately HB-086 was shown to use the gp130 co-receptor as an upstream transducer of Jak-STAT3 signaling1,2.
HB-086 is a strong therapeutic candidate for peripheral neuropathy and associated pain with potential disease modifying properties3.
HB-097 is a ≈30 kDa secreted protein with approximately 40% sequence homonology to HB-086.
HB-097 has been shown to induce in vitro neurite outgrow from dorsal root ganglions via the JAK-STAT3 and MEK-ERK pathway4.
The neuroprotective properties of the protein were investigated in a rodent ototoxicity hearing loss model4.
1 Nishino et al. Meteorin: a secreted protein that regulates glial cell differentiation and promotes axonal extension. The EMBO Journal (2004) 23, 1998–200.
2 Jørgensen et al. Characterization of Meteorin—An Evolutionary Conserved Neurotrophic Factor. J Mol Neurosci. (2009);39(1-2):104-16.
3 Jørgensen et al. Meteorin reverses hypersensitivity in rat models of neuropathic pain. Exp Neurol. (2012);237(2):260-6.
4 Jørgensen et al. Cometin is a novel neurotrophic factor that promotes neurite outgrowth and neuroblast migration in vitro and supports survival of spiral ganglion neurons in vivo. Exp Neurol. (2012)
233(1):172-81.
Neuropathic Pain
With limited treatment options and few recent approvals, a considerable unmet need remains for patients suffering from neuropathic pain. New entries with FDA approval have been sparse with the latest being in 2012 and only 10 new drugs approved, since the first in 1994.
The annual US neuropathic pain market is estimated to USD3.5B with pregabalin and duloxetine as marked leaders.
Neuropathic pain is classified according to whether the underlying cause originates within the peripheral or central nervous system.
The causes of peripheral neuropathic pain are multiple including endocrinological disorders as diabetes, post viral infections (herpes zoster, HIV), use of chemotherapeutics and injury e.g. surgery and trauma.
The estimated prevalence in the general population is 7-9%. With an increasing aging population, prevalence of diabetes and improved survival from cancer after chemotherapy the prevalence is expected to increase
HB-086 is a novel biopharmaceuticals with the potential of becoming an effective, safe and well-tolerated and disease-modifying treatment for peripheral neuropathic pain.
_edited1.jpg?etag=W%2F%22a492-58afffa1%22&sourceContentType=image%2Fjpeg&ignoreAspectRatio&resize=296%2B170&quality=85)
CONTACT US
c/o Cobis
Ole Maaløes vej 3,
DK-2200
keap@hobatherapeutics.com
Tel: +45 31101285
Hoba Therapeutics
Disease modifying treatments for neuropathic pain